Tolterodine Tartrate ER

DRUG3 trials

Sponsors

Urovant Sciences GmbH, University of California, San Francisco

Conditions

IncontinenceIncontinence, UrgeIncontinence, UrinaryOveractive BladderUrinary IncontinenceUrinary Incontinence, Urge

Phase 3

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

CompletedNCT03492281

Urovant Sciences GmbHOveractive Bladder

Start: 2018-03-26End: 2019-02-04Updated: 2021-03-04

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

CompletedNCT03583372

Urovant Sciences GmbHOveractive Bladder

Start: 2018-06-14End: 2019-07-25Updated: 2021-03-18

Phase 4

TReating Incontinence for Underlying Mental and Physical Health

RecruitingNCT05362292

University of California, San FranciscoIncontinence, Incontinence, Urge, Incontinence, Urinary +3

Start: 2022-10-04End: 2027-08-02Target: 270Updated: 2026-03-06

Related Papers

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study

Journal of Comparative Effectiveness Research2023-08-10

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?

Journal of Comparative Effectiveness Research2023-08-10

TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women

Trials2023-04-215 citations

PD38-12 LONG-TERM PATIENT-REPORTED OUTCOMES OF VIBEGRON FOR OVERACTIVE BLADDER: ANALYSES FROM THE EMPOWUR EXTENSION TRIAL

The Journal of Urology2022-04-07

PD38-11 LONG-TERM EFFICACY AND SAFETY OF VIBEGRON FOR OVERACTIVE BLADDER IN PATIENTS ≥65 YEARS OLD: ANALYSIS FROM THE EMPOWUR EXTENSION TRIAL

The Journal of Urology2022-04-07

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

International Journal of Clinical Practice2022-01-0114 citations

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

Advances in Therapy2021-12-1810 citations

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.

2021-01-2016 citations

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study

International Journal of Clinical Practice2020-12-1821 citations